Study of KK8398 for children with achondroplasia
Part of Bones, joints & muscles, Genetic & congenital clinical trials.
This trial tests a new medicine (KK8398) for children with achondroplasia (a common cause of dwarfism). It aims to see if the medicine can help improve bone growth and safety. It may be a good option for children who haven't yet reached their final height and haven't been treated with other growth therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 2.5 and 17.5 years old.
- Your child must have a confirmed genetic diagnosis of achondroplasia (a type of dwarfism).
- Your child's height should be below a certain limit for their age and gender (based on growth charts for children with achondroplasia).
- Your child cannot have received growth hormone or certain bone-growth medicines within the past few months.
- Your child cannot have had previous bone surgery (osteotomy) or be scheduled for such surgery or growth-plate blocking during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine for children with achondroplasia (a common form of dwarfism). It aims to see if the drug can improve growth. The study is for children aged 2.5 to under 11 years old who have not started puberty and can walk without help.
This trial tests a new medicine (ABSK061) for children with achondroplasia, a common form of dwarfism. It aims to see if the drug is safe and can help with growth. Children age 3 to under 12 may qualify.
This trial tests a weekly injection called navepegritide for adolescents aged 12-18 with achondroplasia (a common form of dwarfism). The goal is to see if it can safely improve growth. You must have a genetic confirmation of achondroplasia and a historical height measurement from the past 6 to 15 months.
This study tests an experimental oral medication (TYRA-300) for children with achondroplasia, a common form of dwarfism. The goal is to see if it can safely improve growth in children whose growth plates are still open.
This trial tests a new medicine, BMN 333, against an existing one (vosoritide) to see if it helps children with achondroplasia grow. It's for kids who haven't used these treatments before.
This trial tests a new weekly injection called TransCon CNP for infants with achondroplasia (the most common form of dwarfism). The goal is to see if it can help children grow better than a placebo (a shot with no medicine).
Hear when a new Achondroplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.